Evidence map›Paper›PMID 39123345›Full record

ArticleCancers2024

Utilizing the Metaverse to Provide Innovative Psychosocial Support for Pediatric, Adolescent, and Young Adult Patients with Rare Cancer.

Joe Hasei, Hisashi Ishida, Hideki Katayama, Naoko Maeda, Akihito Nagano, Motoharu Ochi, Masako Okamura, Shintaro Iwata, Kunihiro Ikuta, Shinichirou Yoshida and 5 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joe HaseiDepartment of Medical Information and Assistive Technology Development, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-0082, Japan.ORCID 0000-0002-4028-0786
Hisashi IshidaDepartment of Pediatrics, Okayama University Hospital, Okayama 700-8558, Japan.
Hideki KatayamaDepartment of Palliative and Supportive Care, Okayama University Hospital, Okayama 700-8558, Japan.ORCID 0000-0002-5629-156X
Naoko MaedaDepartment of Pediatrics, NHO National Hospital Organization Nagoya Medical Center, Nagoya 460-0001, Japan.
Akihito NaganoDepartment of Orthopedic Surgery, Graduate School of Medicine, Gifu University, Gifu 501-3822, Japan.
Motoharu OchiDepartment of Pediatrics, Okayama University Hospital, Okayama 700-8558, Japan.
Masako OkamuraDivision of Survivorship, Institute for Cancer Control, National Cancer Center, Tokyo 104-0045, Japan.ORCID 0000-0001-5028-5970
Shintaro IwataDepartment of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0002-2024-514X
Kunihiro IkutaDepartment of Orthopedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya 464-0083, Japan.ORCID 0000-0002-3839-7395
Shinichirou YoshidaDepartment of Orthopedic Surgery, Graduate School of Medicine, Tohoku University, Sendai 980-0872, Japan.
Tomohiro FujiwaraScience of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-0082, Japan.ORCID 0000-0003-4257-9180
Eiji NakataScience of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-0082, Japan.ORCID 0000-0002-5971-4142
Ryuichi NakaharaScience of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-0082, Japan.
Toshiyuki KunisadaScience of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-0082, Japan.ORCID 0000-0002-1775-850X
Toshifumi OzakiScience of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-0082, Japan.ORCID 0000-0003-1732-9307

Funding

Children's Cancer Association of Japan 10JST RISTEX Japan JPMJRS23K1Nippon Life Insurance Foundation Japan noneThe Sanyo Broadcasting Foundation Japan none
6 · The paper itself

Abstract

This study investigated the potential of the metaverse in providing psychological support for pediatric and AYA cancer patients, with a focus on those with rare cancers. The research involved ten cancer patients and survivors from four distinct regions in Japan, who participated in metaverse sessions using customizable avatars, facilitating interactions across geographical and temporal barriers. Surveys and qualitative feedback were collected to assess the psychosocial impact of the intervention. The results demonstrated that the metaverse enabled patients to connect with peers, share experiences, and receive emotional support. The anonymity provided by avatars helped reduce appearance-related anxiety and stigma associated with cancer treatment. A case study of a 19-year-old male with spinal Ewing's sarcoma highlighted the profound emotional relief fostered by metaverse interactions. The findings suggest that integrating virtual spaces into healthcare models can effectively address the unique needs of pediatric and AYA cancer patients, offering a transformative approach to delivering psychosocial support and fostering a global patient community. This innovative intervention has the potential to revolutionize patient care in the digital age.

Indexed as

adolescent and young adultmental healthmetaverserare cancervirtual reality

Identifiers

PMID39123345
PMCPMC11311008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.